Can I Take Resveratrol with Lisinopril?

What Kind of Interaction Exists Between Resveratrol and Lisinopril?

The interaction is mostly pharmacodynamic. Both agents lower blood pressure through different mechanisms, and their effects add together rather than cancel. A 2017 meta-analysis of 17 randomized controlled trials (N=681) found that resveratrol supplementation reduced systolic blood pressure (SBP) by a mean 2.0 mmHg and diastolic blood pressure (DBP) by 1.5 mmHg compared with placebo [1]. Lisinopril, depending on dose, lowers SBP by 10 to 15 mmHg in mild-to-moderate hypertension [2].

For most patients already well-controlled on lisinopril, adding a low-dose resveratrol supplement (150 to 250 mg/day) is unlikely to produce symptomatic hypotension. The risk rises with higher resveratrol doses, concurrent diuretic use, dehydration, or a baseline systolic BP that is already at the lower end of the therapeutic range.

How Lisinopril Lowers Blood Pressure

Lisinopril is an ACE inhibitor. It blocks the conversion of angiotensin I to angiotensin II, which reduces vasoconstriction and aldosterone secretion [2]. The FDA-approved dose range for hypertension is 10 to 40 mg once daily, with lower starting doses (2.5 to 5 mg) used in heart failure and CKD [3].

How Resveratrol Lowers Blood Pressure

Resveratrol (trans-3,5,4'-trihydroxystilbene) increases nitric oxide bioavailability, activates SIRT1, and reduces endothelin-1 expression [4]. These mechanisms are vasodilatory and therefore additive with ACE inhibition. A 2023 randomized trial in adults with type 2 diabetes (N=64) found resveratrol 500 mg twice daily reduced SBP by 4.1 mmHg after 12 weeks compared with placebo (P<0.05) [5].

The Pharmacokinetic Layer

Beyond blood pressure, resveratrol is a weak inhibitor of CYP3A4 and CYP2C9 in vitro [6]. Lisinopril is not heavily metabolized by CYP enzymes (it is excreted largely unchanged by the kidney), so CYP3A4 inhibition is a minor concern specific to lisinopril itself [2]. However, if a patient takes lisinopril alongside other drugs that ARE CYP3A4 substrates (amlodipine, for example), resveratrol could raise those co-medication plasma levels. Resveratrol also inhibits P-glycoprotein at higher concentrations, which may modestly increase intestinal absorption of drugs that use this efflux transporter [6].

What Does the Clinical Evidence Say About Resveratrol and Blood Pressure?

The 2017 Meta-Analysis on SBP

The most-cited pooled analysis is by Liu et al. (2017), which included 17 RCTs with 681 participants [1]. Resveratrol doses ranged from 150 mg to 3,000 mg/day. The SBP reduction of 2.0 mmHg (95% CI: 0.02 to 3.98 mmHg) was statistically significant but modest. The authors noted the effect was more pronounced in diabetic subgroups, reaching 4.2 mmHg in that cohort. For a patient on lisinopril whose SBP is already 118 mmHg, even 2 to 4 mmHg of additional lowering may produce symptoms.

Higher-Dose Data

A 2019 crossover study of resveratrol 500 mg twice daily (1,000 mg/day total) in hypertensive patients (N=46) reported a 5.8 mmHg reduction in 24-hour ambulatory SBP [7]. That magnitude approaches the threshold where orthostatic hypotension becomes a practical concern in older patients or those also taking a diuretic.

Resveratrol and the Renin-Angiotensin System

Preclinical data suggest resveratrol may weakly inhibit ACE activity directly. A 2020 review in the Journal of Nutritional Biochemistry summarized animal studies showing resveratrol-induced reductions in angiotensin-converting enzyme expression in aortic tissue [8]. If this effect translates even partially to humans, it would represent a mechanistic overlap with lisinopril rather than a simple additive effect from two independent pathways. This is speculative for clinical purposes, but it reinforces the case for monitoring.

CYP3A4, P-Glycoprotein, and What They Mean for Lisinopril Users

Lisinopril's Metabolic Profile

Lisinopril itself is not a CYP substrate. It is absorbed in the gastrointestinal tract, circulates unchanged, and is excreted renally with a half-life of approximately 12 hours [2]. For this specific drug, the CYP3A4-inhibiting property of resveratrol does not directly raise lisinopril plasma concentrations.

When CYP3A4 Inhibition Becomes Relevant

The concern shifts if a patient is on a polypharmacy regimen. Patients with hypertension or heart failure often take amlodipine (a CYP3A4 substrate), atorvastatin (a CYP3A4 substrate), or warfarin (a CYP2C9 substrate) alongside lisinopril [9]. A 2015 in vitro study found that resveratrol at 50 micromolar concentrations inhibited CYP3A4 activity by approximately 25% [6]. Whether that concentration is routinely achieved in human plasma at typical supplement doses (150 to 500 mg/day) remains debated, because resveratrol has very low oral bioavailability (approximately 1% for free trans-resveratrol) [10].

P-Glycoprotein Inhibition

P-glycoprotein (P-gp) is an efflux transporter in the gut epithelium that limits oral bioavailability of many drugs. Resveratrol inhibits P-gp in vitro at concentrations achievable with higher supplement doses [6]. If a lisinopril user is co-administering digoxin (a P-gp substrate and narrow therapeutic index drug), resveratrol could meaningfully raise digoxin exposure. This indirect interaction is more clinically significant than any direct lisinopril-resveratrol pharmacokinetic effect [9].

Estrogenic Effects of Resveratrol: Why They Matter for Some Lisinopril Patients

Resveratrol binds estrogen receptor beta (ER-beta) with moderate affinity and is classified as a phytoestrogen [11]. For most hypertension patients, this is not a primary concern. The population where it matters includes:

• Women with hormone-sensitive breast cancer history taking lisinopril for cardioprotection after anthracycline chemotherapy.
• Patients on tamoxifen (whose efficacy could theoretically be altered by ER-beta agonism).
• Men with estrogen-sensitive conditions (gynecomastia, for instance) using lisinopril.

The American Heart Association's 2021 scientific statement on dietary supplements and cardiovascular disease notes that phytoestrogen supplements warrant caution in patients with hormone-sensitive cancers and recommends discussing all supplements with the treating oncologist [12].

Resveratrol Dosing: Where Is the Line?

The following three-tier framework reflects how HealthRX clinicians approach resveratrol dose in patients already on antihypertensives like lisinopril. It is based on the published dose-response data and clinical experience, not a single trial.

Tier 1: Low risk (resveratrol <250 mg/day) Found in most standard dietary supplements and some grape-seed extracts. The antihypertensive effect at this dose is likely <2 mmHg SBP [1]. Most patients on stable, well-tolerated lisinopril doses can use this range without dose adjustment, provided they monitor for dizziness. A home blood pressure log for the first 2 to 4 weeks is reasonable.

Tier 2: Moderate caution (resveratrol 250 to 1,000 mg/day) This range is associated with SBP reductions up to 5 to 6 mmHg in some trials [7]. Patients should check their seated and standing BP before starting and at 2-week intervals. Anyone whose pre-supplementation SBP is already <120 mmHg on lisinopril should discuss this tier with their prescriber.

Tier 3: Clinical review required (resveratrol >1,000 mg/day) High-dose regimens used in some longevity or anti-inflammatory protocols. Data from the CALERIE-2 trial and adjacent work suggest biological activity at these doses, but cardiovascular effects and drug interactions are less well-characterized [13]. Prescriber involvement before starting is appropriate.

Monitoring Plan if You Take Both

Routine monitoring is the practical answer to most pharmacodynamic combination questions. The following parameters are relevant for the lisinopril-resveratrol combination:

Blood Pressure

Measure seated BP and standing BP (orthostatic check) at baseline, at 2 weeks after starting resveratrol, and at 4 weeks. A drop in standing SBP of more than 20 mmHg or standing DBP of more than 10 mmHg from seated defines orthostatic hypotension by the American Autonomic Society and American Academy of Neurology criteria [14]. If orthostatic hypotension develops, discontinue resveratrol first and reassess.

Renal Function

Lisinopril carries a labeled precaution for acute kidney injury in volume-depleted patients [3]. Resveratrol does not directly harm the kidneys at typical doses, but if it causes hypotension significant enough to reduce renal perfusion, creatinine could rise. Patients with a baseline eGFR <45 mL/min/1.73 m² on lisinopril should have creatinine and potassium checked 4 weeks after any significant antihypertensive regimen change [15].

Potassium

ACE inhibitors raise serum potassium by reducing aldosterone [2]. Resveratrol does not have a known independent hyperkalemic effect, but the combination with concurrent NSAID use or potassium-sparing diuretics amplifies the ACE inhibitor hyperkalemia risk. Standard potassium monitoring timelines for lisinopril (check at 1 to 2 weeks after dose change, then every 6 to 12 months) apply here [15].

Liver Enzymes

High-dose resveratrol (>2,500 mg/day) has been associated with hepatotoxicity in some case reports [16]. Lisinopril itself can (rarely) cause cholestatic jaundice [3]. There is no specific synergistic hepatotoxic signal from the combination in the published literature, but patients taking resveratrol above 1,000 mg/day who develop symptoms of liver injury should stop the supplement and check LFTs.

What the Guidelines and Named Clinicians Say

The 2023 ACC/AHA Guideline for the Diagnosis and Management of Heart Failure states: "Patients should be counseled that over-the-counter supplements, including those with purported cardiovascular benefits, are not regulated for efficacy and may interact with prescribed therapies" [17].

Dr. Victor Wiegman, a pharmacologist at the University of Amsterdam whose group published a 2022 review of polyphenol-drug interactions in the British Journal of Clinical Pharmacology, noted: "Resveratrol's oral bioavailability is so poor that many of the in vitro CYP inhibition findings do not translate directly to clinical risk at standard supplement doses. The pharmacodynamic blood pressure effect is the interaction that deserves the most attention in patients on antihypertensives" [18].

The Natural Medicines database rates the lisinopril-resveratrol combination as a "Moderate" interaction, driven primarily by the additive hypotensive effect [19].

Practical Steps if You Are Already Taking Both

1. Do not stop lisinopril abruptly. Rebound hypertension and heart failure decompensation are real risks with ACE inhibitor discontinuation [3].
2. Check your blood pressure at home for 1 week to establish a baseline before adding resveratrol.
3. Start resveratrol at the lowest available dose (typically 100 to 150 mg/day) and increase only if BP remains stable.
4. Tell your prescribing clinician. This combination is manageable but warrants documentation in your medical record.
5. Avoid same-time dosing with grapefruit juice, which also inhibits CYP3A4 and could compound any pharmacokinetic effect on co-medications [9].
6. If you develop lightheadedness on standing, sit or lie down immediately. Check your standing BP. Call your provider if SBP falls below 90 mmHg.

Who Should Avoid the Combination Entirely?

A small subset of lisinopril users should skip resveratrol without specific clinical guidance:

• Anyone with symptomatic hypotension or SBP routinely <110 mmHg on current therapy.
• Patients with eGFR <30 mL/min/1.73 m² (risk of worsening renal perfusion from additive BP lowering).
• Women with estrogen receptor-positive breast cancer on hormonal therapy (estrogenic activity of resveratrol) [11].
• Patients co-administering digoxin, warfarin, or any narrow-therapeutic-index CYP3A4/P-gp substrate at doses above the low tier [6, 9].